Background Image


  1. Mason BN, Hassler SN, DeFea K, Boitano S, Vagner J, Price T, Dussor G, PAR2 activation in the dura causes acute behavioral responses and priming to glyceryl trinitrate in a mouse migraine model, J. Headache and Pain, IN PRESS, 2023.
  2. Kume M,  Ahmad A, DeFea K.A., Vagner J., Dussor G., Boitano S., Price T.J, Protease-Activated Receptor 2 (PAR2) expressed in sensory neurons contributes to signs of pain and neuropathy in paclitaxel treated mice. Journal of Pain, IN PRESS 2023.
  3. Kume M., Ahmad A., Shiers S., Burton M.D., DeFea K.A., Vagner J., Dussor G., Boitano S., Price T.J. C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 (PAR2), Displays in vivo Efficacy Against Protease-Induced Pain in Mice; Journal of Pain, Nov. 20, 2022, 10.1016/j.jpain.2022.11.006, PMID: 36417966
  4. Schiff H. V., Rivas C. M., Pederson W.,  P.Sandoval E., Gillman S., Prisco J., Kume M., Dussor G., Vagner J., Ledford J. G., Price T. J., DeFea K. A., Boitano S.; β-arrestin-biased proteinase-activated receptor-2 antagonist C781 limits allergen-induced airway hyperresponsiveness and inflammation. June 23, 2022, Br J Pharmacol,; PMID: 35735078
  5. Rivas CM, Yee MC,  Addison KJ,  Lovett M, Pal K,  Ledford JG,  Dussor G,  Price TJ,  Vagner J,  DeFea KA,  Boitano S. Novel proteinase-activated receptor-2 (PAR2) antagonist C391 inhibits Alternaria-induced human airway epithelial signaling in vitro and asthma indicators in acute exposure murine models, Br J Pharmacol. 2022, 179(10): 2208-2222; PMID: 34841515
  6. Rivas CM, Schiff HV, Moutal A, Khanna R, Kiela PR, Dussor G, Price TJ, Vagner J, DeFea KA, Boitano S. Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression. Biochemical and Biophysical Research Communications (2022).591: 13-19.; PMID: 35295409